CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well as the feasibility of a flexible manufacturing schema in adult patients with B cell malignancies that have failed prior therapies.

Trial Details

NCT ID
NCT04186520
Phase
PHASE1 / PHASE2
Sponsor
Medical College of Wisconsin
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • 8/12-Day Production of Car-T Cells
  • 8/12-Day Production of Cryopreserved Car-T Cells
  • 12-Day Production of Car-T Cells
Locations (sample)
  • Milwaukee, Wisconsin, United States|43.0389,-87.90647

Key Eligibility Criteria

  • Patients must be aged ≥18 years and ≤80 years with relapsed or refractory B-cell non-Hodgkin Lymphoma.
  • Absolute cluster of differentiation 3 (CD3) count ≥50 mm\^3.
  • Magnetic resonance imaging (MRI) brain and lumbar puncture with cerebrospinal fluid (CSF) analysis by cytology and flow cytometry without evidence …
  • Measurable disease must be documented within four weeks of the time of consent defined as nodal lesions greater than 15 mm in the long axis or extr…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →